EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Microba Life Sciences's Enterprise Value is €10.40 Mil.
Microba Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-10.50 Mil. Therefore, Microba Life Sciences's EV-to-FCF for today is -0.99.
The historical rank and industry rank for Microba Life Sciences's EV-to-FCF or its related term are showing as below:
FRA:F3Y'
s EV-to-FCF Range Over the Past 10 Years
Min: -5.94 Med: -2.42 Max: -0.16
Current: -1
During the past 4 years, the highest EV-to-FCF of Microba Life Sciences was -0.16. The lowest was -5.94. And the median was -2.42.
FRA:F3Y's EV-to-FCF is ranked worse than 100% of 98
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.465
vs FRA:F3Y: -1.00
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Microba Life Sciences (FRA:F3Y) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Microba Life Sciences's PE Ratio (TTM) for today is calculated as:
Microba Life Sciences's share price for today is €0.0175.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Microba Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.022.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Microba Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microba Life Sciences EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Microba Life Sciences's EV-to-FCF falls into.
Microba Life Sciences's current Enterprise Value is €10.40 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Microba Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-10.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microba Life Sciences (FRA:F3Y) has a EV-to-FCF of -0.99 as of Jul. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Microba Life Sciences and its competitors. According to the industry distribution chart, Microba Life Sciences ranks #999999 out of 98 companies in the Medical Diagnostics & Research industry.
Is Microba Life Sciences' EV-to-FCF too high?
Microba Life Sciences' current EV-to-FCF is -0.99. Based on the distribution chart, Microba Life Sciences ranks #999999 out of 98 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Microba Life Sciences has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Microba Life Sciences' EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Microba Life Sciences ranks #999999 out of 98 companies for EV-to-FCF. This places Microba Life Sciences in the lower half of its industry. The industry median EV-to-FCF is 22.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.47, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Microba Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microba Life Sciences's current EV-to-FCF is -0.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Microba Life Sciences (FRA:F3Y) has a current EV-to-FCF of -0.99. The stock's GF Value™ is €0.12, compared to a current price of €0.02 — trading 85.4% below its estimated fair value. The current EV-to-FCF is -0.99. Microba Life Sciences' overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Microba Life Sciences (FRA:F3Y), the current EV-to-FCF is -0.99 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Microba Life Sciences (FRA:F3Y) Overvalued in 2026?
Based on GuruFocus' analysis, Microba Life Sciences stock appears to be undervalued.
The current stock price of €0.02 is trading 85.4% below its estimated GF Value™ of €0.12.
Key valuation signals for FRA:F3Y:
EV-to-FCF: -0.99
GF Value™: €0.12 vs. price of €0.02 (85.4% below fair value)
No single metric tells the full story. See the FRA:F3Y stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
29GF Score
Get the complete analysis for FRA:F3Y
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F3Y has been successfully added to your 
